Benitec Ltd Company Profile

News Articles [ 34 Associated News Articles listed on BioPortfolio]

uniQure licenses RNA interference technology to advance Huntington’s disease program

uniQure B.V. announced a non-exclusive cross-licensing agreement with Benitec Biopharma Ltd. giving uniQure access to Benitec’s proprietary DNA-directed RNA interference (ddRNAi) technology in Hunti...

Australia's Benitec to acquire US RNAi firm Tacere

Australia-based Benitec Biopharma (ASX: BLT) said last Friday that it has executed an agreement to acquire the privately-held US RNA interference (RNAi) therapeutics company Tacere Therapeutics.

Benitec to conduct phase I/II clinical trial of TT-034 in patients with HCV in UCSD site

RNAi-based therapeutics company Benitec Biopharma Limited today announced the selection of the University of California, San Diego, Health Sciences as the second site for its upcoming phase I/II first...

Benitec gains hepatitis C drug with Tacere buyout

Benitec Biopharma agreed to buy Tacere Therapeutics, whose hepatitis C drug candidate TT-034 is based on Benitec's gene-silen -More- 

uniQure, Benitec enter into non-exclusive cross-licensing agreement

uniQure has entered into a non-exclusive cross-licensing agreement to gain access to Benitec's proprietary DNA-directed RNA interference (ddRNAi) technology to advance its research in the development...

Benitec selects Duke Clinical Research Unit as a site for HCV phase I/II trial

RNAi-based therapeutics company Benitec Biopharma has selected the Duke Clinical Research Unit, the early phase unit of the Duke Clinical Research Institute (DCRI) of Durham, N.C., as a site for its u...

International Experts in RNAi Therapeutics Join Benitec’s Inaugural Chief Investigators Group to Help Deliver Excellence and Innovation Across its Therapeutic Programs

18 February 2011, Melbourne, Australia: Benitec Ltd (ASX: BLT), a world leader in expressed gene silencing for human therapeutics, today announces the formation of the Benitec Chief Investigators...

[Genable] gets rights to use [Benitec]'s ddRNAi technology with GT038

Gene therapy company [Genable Technolgies Ltd.] has licensed exclusive global rights to use [Benitec Biopharma Ltd.]’s (RNAi-based therapeutics) DNA-directed RNAi (ddRNAi) gene-silencing technology...

Drugs and Medications [0 Results]

None

PubMed Articles [0 Results]

None

Clinical Trials [0 Results]

None

Companies [ 2 Associated Companies listed on BioPortfolio]

Benitec Limited

Benitec Ltd. is a leading international biotechnology company listed on the Australian Stock Exchange. Benitec was founded in 1997 to commercialize research from Queensland's Department of Primary Ind...

Benitec Ltd

Benitec Limited is developing new novel treatments for chronic and life-threatening conditions based on a transformational technology, DNA-directed RNA interference (ddRNAi) - som...